---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087876"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:21:23.542333+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Iovance updates corporate presentation; FY24 product revenue guidance $160-165M, Q2 revenue $31.1M

## Summary
- FY2024 product revenue guidance of $160-165 million; Q2 2024 net product revenue $31.1 million.
- Cash and investments ~$450 million as of July 24, 2024, after ~$200M ATM equity raise in Q2-Q3 2024.
- 51 Authorized Treatment Centers as of Aug 8, 2024; >225M patient lives covered; >55 patients treated.
- Pipeline: TILVANCE-301 Phase 3 frontline melanoma enrolling; IOV-LUN-202 NSCLC registrational data expected 2025.
- IOV-END-201 Phase 2 proof-of-concept trial in endometrial cancer initiated; IOV-4001 PD-1 inactivated TIL in Phase 1/2.

## SEC filing metadata
- accession: 0001104659-24-087876
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924087876/0001104659-24-087876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924087876/tm2421344d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087876
- JSON: https://secwatch.observer/filing/0001104659-24-087876.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.